  In toxicological risk assessment the benchmark dose (BMD) is recommended
instead of the no-observed-adverse effect-level (NOAEL). Still a simple test
procedure to estimate NOAEL is proposed here, explaining its advantages and
disadvantages. Versatile applicability is illustrated using four different data
examples of selected in vivo toxicity bioassays.
